Health Affairs July 20, 2022
Gabriela Gracia, Frank S. David, Rena M. Conti

Following on the Lower Drug Costs Now Act (H.R.3) and the Reduced Costs and Continued Cures Act (H.R.5260), Senate Democrats have now agreed on new language seeking to rein in the prices of prescription drugs to improve access and affordability; if approved by the Senate parliamentarian, the new language would be part of a scaled-down reconciliation package dealing with health care, climate change, and other issues.

All these proposals would provide for the Secretary of Health and Human Services (HHS) to negotiate prices for select drugs on behalf of patients. The new language and H.R.3 would allow HHS to penalize companies for price increases in excess of the rate of inflation; H.R. 3 was projected by the Congressional Budget Office to save...

Today's Sponsors

Transcarent
SalesSparx

Today's Sponsor

Health Edge

 
Topics: Biotechnology, Investments, Pharma / Biotech, Survey / Study, Trends
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries
Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests
Pfizer and Ada Health Inc. To Launch Nationwide Online COVID-19 Care Journey
Chutes & Ladders—Ginkgo BioWorks CEO to lead federal biotech commission
Smoothing Medicare Part D Out-Of-Pocket Costs Under The Inflation Reduction Act

Share This Article